Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction
Stroke
DOI:
10.1016/j.jacadv.2024.101566
Publication Date:
2025-01-18T19:52:48Z
AUTHORS (13)
ABSTRACT
Limited data exist on the long-term impact of beta-blocker therapy after percutaneous coronary intervention (PCI) in patients with stable artery disease (CAD) and preserved left ventricular ejection fraction (LVEF). The aim study was to evaluate effects early initiation vs no following PCI CAD LVEF. This retrospective cohort employed target trial emulation incident user design, utilizing TriNetx database (2009-2024). Early (within days 1 7) compared using 1:1 greedy propensity score matching. outcomes included all-cause mortality, hospitalization for myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, safety endpoints. Hospitalization bone fracture acute appendicitis served as falsification In intention-to-treat analysis, were analyzed over 5 years Cox-proportional hazards. Out 11,681 matched per group, associated increased mortality (HR: 1.11 [95% CI: 1.09-1.18]). No significant differences found infarction 1.03 0.97-1.09]), stroke 0.98 0.91-1.05]), failure 0.99 0.95-1.03]), fibrillation/flutter 0.97 0.93-1.01]). hypotension higher beta-blockers 1.10 1.06-1.14]). 1.02 0.85-1.22]) 1.17 0.95-1.45]) showed associations. Several sensitivity analyses consistent results. LVEF cardiovascular events.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....